Key Highlights
- Johnson & Johnson (JNJ) shares tumble 5.39% even after surpassing Q3 profit projections.
- The company posted $25.4 billion in third-quarter sales, exceeding the $25.28B consensus.
- MedTech segment underperforms as global market challenges impact JNJ’s medical device business.
- TREMFYA achieves remarkable 68% growth, reaching $2.4 billion in quarterly sales.
- The healthcare giant plans mid-2027 separation of DePuy Synthes orthopedics operations.
Shares of Johnson & Johnson (JNJ) tumbled 5.39% to close at $249.51 on Tuesday, shedding $14.22 in value despite delivering third-quarter results that exceeded analyst projections. While the pharmaceutical segment demonstrated robust momentum and the company elevated its annual forecast, disappointing MedTech results and challenges in overseas markets triggered the sell-off.
Third-Quarter Results Exceed Projections as JNJ Lifts Annual Forecast
Johnson & Johnson delivered third-quarter sales of $25.4 billion, topping the Street’s $25.28 billion projection. The healthcare conglomerate posted adjusted profit of $2.59 per share, beating the consensus estimate of $2.54. Operational revenue climbed 6%, driven primarily by strength in the company’s drug portfolio.
Management increased its full-year reported sales outlook to roughly $101.2 billion from the prior estimate of $101.1 billion. The adjusted profit guidance midpoint also rose to $11.10 per share versus the previous $11.04. CEO Joaquin Duato credited new product introductions and ongoing innovation for the quarter’s performance.
Looking to 2026, Johnson & Johnson’s management projects operational revenue expansion between 6.7% and 7.1%. The firm anticipates crossing the $100 billion annual revenue threshold for the first time in its history. Leadership indicated that strategic capital allocation would fuel double-digit expansion by 2030.
Medical Device Segment Underperformance Triggers Investor Concerns
Despite the earnings beat, Johnson & Johnson’s MedTech operations grew operational sales by only 2.5% during the quarter. The division generated $8.6 billion in revenue, falling short of Wall Street’s $8.71 billion forecast. Weakness in cardiovascular and surgery product lines, especially in markets beyond U.S. borders, contributed to the shortfall.
CFO Joe Wolk outlined multiple headwinds affecting the company’s global medical device operations. Ongoing conflict in the Middle East has curtailed healthcare expenditures across that region, while European governments implementing cost-containment measures reduced demand. Additionally, aggressive pricing actions in China and persistent underperformance at the ABIOMED cardiac pump division constrained growth.
The pharmaceutical arm delivered superior results, with quarterly revenue advancing 7.7% to $16.76 billion. TREMFYA posted exceptional growth, with sales jumping 68% to $2.4 billion and surpassing analyst projections of roughly $2.19 billion. DARZALEX revenue expanded approximately 16% to $4.24 billion, though this figure came in below market consensus.
DePuy Synthes Separation Targeted for Completion by Mid-2027
Johnson & Johnson remains on track to separate its DePuy Synthes orthopedic device business by the middle of 2027. Leadership currently prefers a tax-free spin-off transaction as the company refocuses on faster-growing pharmaceutical and medical technology segments. This restructuring would represent another significant portfolio reshaping following the Kenvue consumer health separation.
Media reports from September suggested Apollo Global Management had explored potential acquisition discussions regarding the orthopedics unit. Those accounts indicated a deal might value the business around $20 billion. Nevertheless, management has yet to finalize the transaction approach and continues weighing all strategic alternatives.
Johnson & Johnson concluded the third quarter holding approximately $17 billion in cash and liquid investments. The balance sheet also carried $45 billion in outstanding debt, while the company generated more than $6 billion in quarterly free cash flow. Management anticipates delivering roughly $21 billion in free cash flow for the full year while executing product launches and advancing restructuring initiatives.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
